MIRA PHARMACEUTICALS, INC. 8-K

What Happened
MIRA Pharmaceuticals, Inc. filed a Form 8-K on July 6, 2026 and issued a press release announcing positive preclinical results for the company’s optimized oral formulation of SKNY-1, its drug candidate for obesity and addiction-related disorders. The studies showed favorable oral bioavailability, reproducible systemic exposure, robust brain penetration, and substantial liver exposure after oral dosing. The company reported peak plasma concentrations and kinetics that support the potential for once-daily oral dosing. The press release is attached as Exhibit 99.1 to the filing.

Key Details

• Filing date: July 6, 2026 (Form 8-K); press release attached as Exhibit 99.1.
• Pharmacokinetics: favorable oral bioavailability, reproducible systemic exposure, robust brain penetration, and substantial liver exposure reported.
• Dosing implication: peak plasma concentrations and kinetics support potential once-daily oral dosing.
• Context: findings complement prior preclinical efficacy and behavioral studies showing weight reduction, preservation of lean mass, metabolic improvements, reduced compulsive feeding and nicotine-seeking, and no anxiety-related behavioral effects in validated models.

Why It Matters
These pharmacokinetic results strengthen SKNY-1’s preclinical development profile by showing the optimized oral formulation delivers meaningful systemic and brain exposure and may allow convenient once-daily dosing—important practical factors for patient adherence and clinical development. For investors, the announcement is a non-financial development that may reduce formulation- and dosing-related uncertainty in future clinical planning; it does not provide clinical trial timelines, regulatory milestones, or financial guidance.